跳至主要内容
临床试验/NCT00891228
NCT00891228已完成1 期

A Multicenter, Randomized, Double-Blind Comparator Trial of the Safety and Sperm and Gonadotropin Suppression Resulting From Combined Use of Nestorone® Gel (0, 8 or 12 mg NES) and Testosterone Gel (10 g) Compared With Testosterone Gel in Normal Men

Health Decisions2 个研究点 分布在 1 个国家目标入组 99 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
99
试验地点
2
主要终点
The Number of Men Who Have Suppression of Sperm Production ≤1Million/mL Million/mL When Using a Daily Regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel Applied Transdermally.

研究概览

简要总结

To determine the number of men who have suppression of sperm production when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Men who meet any of the following criteria are NOT eligible for enrollment in the trial:
  • Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit
  • Men not living in the catchment's area of the clinic or within a reasonable distance from the site
  • Clinically significant abnormal findings at screening
  • Elevated PSA (levels ≥ 4 ng/mL), according to local laboratory normal values
  • Abnormal serum chemistry values, according to local laboratory normal values that indicate liver or kidney dysfunction or that may be considered clinically significant. Other abnormal lab values may also be exclusionary, at the discretion of the investigator
  • Sperm concentration below 15 million/mL in more than one of three screening samples
  • Use of androgens or body building substances within 6 months before first screening visit
  • Diastolic (D) blood pressure (BP) ≥ 85 and Systolic (S) BP ≥ 135 mm Hg; (BP will be taken 3 times at 5 minute intervals and the mean of all measurements be considered)
  • History of hypertension, including hypertension controlled with treatment
  • Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis
  • Known hypersensitivity to progestins
  • Family or personal history of venous thromboembolism
  • Benign or malignant liver tumors; active liver disease
  • History of breast carcinoma
  • Known history of reproductive dysfunction including vasectomy or infertility
  • Known history of cardiac, renal, hepatic or prostatic disease
  • A serious systemic disease such as diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above)
  • History of sleep apnea
  • Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance
  • Known dermatitis or severe skin disorder
  • Partner is known to be pregnant
  • Men desiring fertility within the first 24 weeks of study participation.
  • Men participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status.

研究组 & 干预措施

Testosterone Gel 10 g and Nestorone® 0 mg per day

Placebo Comparator

Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.

干预措施: Testosterone (Drug)

Testosterone Gel 10 g and Nestorone® 0 mg per day

Placebo Comparator

Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.

干预措施: Nestorone® (Drug)

Testosterone Gel 10 g and Nestorone® 8 mg per day

Experimental

Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.

干预措施: Testosterone (Drug)

Testosterone Gel 10 g and Nestorone® 8 mg per day

Experimental

Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.

干预措施: Nestorone® (Drug)

Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day

Experimental

Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.

干预措施: Testosterone (Drug)

Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day

Experimental

Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.

干预措施: Nestorone® (Drug)

结局指标

主要结局

The Number of Men Who Have Suppression of Sperm Production ≤1Million/mL Million/mL When Using a Daily Regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel Applied Transdermally.

时间窗: 24 Weeks

次要结局

  • The Number of Men Who Have Suppression of Sperm Production ≤3 Million/mL ≤ 3 Million/mL or Azoospermia When Using a Daily Regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel.(24 Weeks)
  • The Number of Men Who Have Azoospermia(24 Weeks)
  • The Impact on Sperm Motility in Men Who Are Not Azoospermic Azoospermic.(24 Weeks)
  • The Impact on Sperm Morphology in Men Who Are Not Azoospermic(24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验